Application of oxalis corniculata or extract of oxalis corniculata in preparation of medicine for preventing and / or treating infectious serositis of poultry

The drugs prepared through oxalis water extract solve the prevention and treatment problems of infectious serositis in poultry, significantly reduce the mortality rate and inflammatory manifestations of the disease, and provide a more effective anti-inflammatory solution.

CN119015331AActive Publication Date: 2024-11-26BEIJING CENT BIOLOGY CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411319713.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-26
Estimated Expiration
2044-09-20

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat poultry infectious serositis, especially when drug-resistant strains are common, and common anti-inflammatory Chinese medicinal materials are not effective in poultry, resulting in the demand for poultry-specific anti-inflammatory drugs. urgent.

Method used

Oxalis or its aqueous extracts are used as pharmaceutical ingredients, extracted by decoction and filtration, combined with carrier and excipients, and prepared into oral preparations for the prevention and treatment of infectious serositis and inflammatory diseases in poultry.

Benefits of technology

Oxalis extract significantly reduces the mortality rate and pericardial liver rate of poultry infectious serositis, has better anti-inflammatory effects than other common Chinese herbal medicines, and can be used as an effective prevention and treatment method for poultry.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005056356000000061
    Figure BDA0005056356000000061
  • Figure BDA0005056356000000062
    Figure BDA0005056356000000062
  • Figure BDA0005056356000000081
    Figure BDA0005056356000000081
Patent Text Reader

Abstract

The invention relates to application of oxalis corniculata or an extract thereof in preparation of a medicine for preventing and / or treating poultry infectious serositis and poultry inflammatory diseases. Experiments prove that the oxalis corniculata or the oxalis corniculata extract can effectively prevent and treat poultry inflammatory diseases for the first time, and the oxalis corniculata or the oxalis corniculata extract has a more prominent effect than other common anti-inflammatory traditional Chinese medicines; the compound can effectively prevent and treat poultry infectious serositis (such as duck infectious serositis caused by infection of riemerella anatipestifer), so that the compound is expected to become a medicine for treating poultry inflammatory diseases and poultry infectious serositis, and has great application prospect and value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to use of Oxalis or an extract thereof in preparing a drug for preventing and / or treating poultry infectious serositis and a drug for preventing and / or treating poultry inflammatory diseases. Background Art

[0002] Duck infectious serositis is a contact, acute or chronic, septicemic infectious disease caused by Riemerella anatipestifer in ducks, geese and other poultry and wild birds. It mainly affects ducklings aged 1-8 weeks. Clinical symptoms include eye and nasal discharge, green diarrhea, ataxia and convulsions. Chronic cases may have neurological symptoms. Pathological characteristics include fibrinous pericarditis, perihepatitis, air sacculitis, caseous salpingitis, arthritis and paralysis. Duck infectious serositis is a common disease in the breeding frontline and one of the main infectious diseases that endanger the duck farming industry, often causing serious economic losses. The abuse of antibiotics is common in duck production, and drug resistance is very common in many areas. As the problem of drug-resistant strains becomes more and more serious, the requirements for disease prevention and control are also getting higher and higher.

[0003] Duck infectious serositis can cause inflammatory phenomena such as pericarditis. With the increase in clinical drug resistance problems in veterinary drugs, pure Chinese medicine products, as one of the solutions, have a broader application space. Finding Chinese medicinal materials with good preventive and therapeutic effects on this type of disease is an urgent need of the industry.

[0004] There are many Chinese medicinal materials with antibacterial and anti-inflammatory effects. Finding Chinese medicinal materials that can play a significant role in poultry farming is a key task in veterinary drug research and development. Due to the differences in the physiological functions of mammals and poultry, medicinal materials that have a good effect in mammals may not be able to replicate the same effect in poultry diseases. In particular, poultry are mostly administered in groups, and many personalized dosing plans cannot achieve good results in poultry farming. Therefore, finding anti-inflammatory drugs specifically for poultry is an urgent need for drug development.

[0005] Oxalis is a perennial herb with slender rhizomes, thin and weak stems, often brown, creeping or oblique, many branches, and soft hairs. Oxalis tastes sour, with three leaflets, so it is called Oxalis, Physalis, sour grass, sour grass, trifoliate sour grass, etc. It has the functions of clearing away heat and dampness, cooling blood and dispersing blood stasis, detoxifying and reducing swelling. It is mainly used for damp-heat diarrhea, dysentery, jaundice, stranguria, leucorrhea, hematemesis, epistaxis, hematuria, irregular menstruation, traumatic injury, sore throat, carbuncle, erysipelas, eczema, scabies, hemorrhoids, measles, burns, snake and insect bites. In addition, Oxalis has the effect of clearing the heart and calming the mind, and can be used with pine needles and jujube to treat insomnia, dreaminess, and forgetfulness caused by heart heat. Summary of the invention

[0006] Purpose of the Invention

[0007] In view of the defects or needs in the above-mentioned prior art, the purpose of the present invention is to use Oxalis or its extract in the preparation of drugs for preventing and / or treating poultry infectious serositis and drugs for preventing and / or treating poultry inflammatory diseases.

[0008] Solution

[0009] To achieve the above object, the present invention adopts the following technical solution:

[0010] In a first aspect, the present invention provides use of Oxalis oxalis or an extract thereof in the preparation of a medicament for preventing and / or treating poultry infectious serositis.

[0011] In a feasible embodiment of the above use, the poultry infectious serositis is selected from duck infectious serositis, goose infectious serositis and chicken infectious serositis.

[0012] Preferably, the poultry infectious serositis is duck infectious serositis.

[0013] Further preferably, the duck infectious serositis is caused by Riemerella anatipestifer.

[0014] In the above use, it is feasible that the treatment of poultry infectious serositis includes one or more of the following:

[0015] (1) Slow down the progression of poultry infectious serositis;

[0016] (2) Improve the symptoms caused by poultry infectious serositis, including pericarditis, perihepatitis, air sacitis, caseous salpingitis, arthritis and paralysis caused by poultry infectious serositis.

[0017] In a second aspect, the present invention provides use of Oxalis oxyphylla or an extract thereof in the preparation of a medicament for preventing and / or treating poultry infectious serositis.

[0018] For the above two uses, it is feasible that the Oxalis sorrel extract is a water extract of Oxalis sorrel.

[0019] In a preferred embodiment, the water extract of Oxalis oxyphylla is prepared by the following method:

[0020] S1: decoct Oxalis with water to extract, and filter the extract;

[0021] S2: The above decoction and filtration procedures are repeated several times;

[0022] S3: The multiple filtrates obtained in step S2 are combined and concentrated to obtain.

[0023] Preferably, in step S1, 10-15 times the amount of water is used to decoct the Oxalis powder for extraction; the "times" here refers to the multiple of mass, for example, 1 kg of medicinal material, plus 10 kg of water is called 10 times the amount of water;

[0024] Preferably, in step S1, each decoction time is 1-2 hours;

[0025] Preferably, in step S2, the decoction and filtration procedures are repeated 2-3 times;

[0026] Preferably, in step S3, the concentration is reduced-pressure concentration, preferably concentrated to a crude drug content of 0.3 to 2 g / mL, preferably 0.5 to 1 g / mL; the "crude drug content" here is used to describe the relationship between the mass of the original medicinal material and the volume of the concentrated solution obtained after extraction and concentration, specifically refers to the mass of the original medicinal material contained in a unit volume of concentrated solution; for example, a crude drug content of 1 g / ml refers to: the crude drug content of 1000 ml of concentrated solution obtained by extracting 1000 g of medicinal materials and concentrating them to 1000 ml.

[0027] For the above two uses, preferably, the drug comprises a preventive and / or therapeutically effective amount of Oxalis sorrel or an extract thereof, and optionally, a veterinarily acceptable carrier and / or excipient.

[0028] Preferably, the drug is a drug with the Oxalis or its extract as the sole active ingredient, or a pharmaceutical composition with it as one of the active ingredients.

[0029] Preferably, the drug is administered orally, including but not limited to administration by drinking water and administration mixed with feed.

[0030] Preferably, the drug is administered orally, including mixing with feed, administering with drinking water, or directly administering orally.

[0031] Further practicable, the drug can also be prepared into an oral preparation, such as an oral solution, suspension, tablet, capsule, etc.

[0032] In a third aspect, the present invention provides a method for preventing and / or treating infectious serositis in poultry, the method comprising: administering a preventive and / or therapeutically effective amount of Oxalis or an extract thereof to poultry in need thereof.

[0033] In a fourth aspect, the present invention provides a method for preventing and / or treating inflammatory diseases in poultry, the method comprising: administering a preventively and / or therapeutically effective amount of Oxalis or an extract thereof to poultry in need thereof.

[0034] The term "effective amount" refers to the amount or dosage of an active ingredient that provides the desired effect on the diagnosed or treated sick poultry through single or multiple administrations to the sick poultry. The effective amount can be determined by the veterinarian involved in the diagnosis as a person skilled in the art through known techniques and observations obtained under similar circumstances. In determining the effective amount or dosage of the active ingredient to be administered, the veterinarian involved in the diagnosis should consider a variety of factors, including but not limited to: the degree of involvement or severity of the disease; the mode of administration; and other relevant circumstances.

[0035] Beneficial Effects

[0036] The inventors of the present invention have found, through extensive screening, that Oxalis or its extract has a good effect in preventing and treating poultry infectious serositis and poultry inflammatory diseases, and further provide the use of Oxalis or its extract in preparing a drug for preventing and / or treating poultry infectious serositis and poultry inflammatory diseases. The inventors have confirmed through experiments that Oxalis or its extract can prevent and treat poultry inflammatory diseases, and has a more prominent effect than other common anti-inflammatory Chinese medicines; and Oxalis or its extract can effectively prevent and treat poultry infectious serositis (for example, duck infectious serositis caused by Riemerella anatipestifer infection), which is specifically manifested in that it can significantly reduce the mortality rate and pericardial perihepatic rate of poultry caused by poultry infectious serositis. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.

[0038] Figure 1 The liver autopsy results of ducks in the blank control group (Figure A) and the duck infectious serositis model group (Figure B) are shown. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described in conjunction with the embodiments below. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0040] In addition, in order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can also be implemented without certain specific details. In some embodiments, raw materials, elements, methods, means, etc. well known to those skilled in the art are not described in detail, so as to highlight the main purpose of the present invention.

[0041] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.

[0042] The present invention is further described in detail below by way of examples.

[0043] In the following examples, unless otherwise specified, all raw materials are commercially available products.

[0044] 1. Preparation of aqueous extracts of Chinese herbal medicines

[0045] The Oxalis, Sophora flavescens, Phellodendron chinense, Lonicera japonica, and Radix Isatidis used in the following examples and comparative examples were all purchased from Anguo Jufu Chinese Medicinal Materials Co., Ltd. and all met the pharmacopoeia standards.

[0046] Example 1: Preparation of Oxalis Sorrel Water Extract

[0047] 100 parts of Oxalis Sorrel were added with 10 times the amount of water and boiled for 2 times, each time for 1 hour, the filtrates were combined, and the mixture was concentrated under reduced pressure to a crude drug content of 1 g / mL.

[0048] Example 2: Preparation of Oxalis Sorrel Water Extract

[0049] 100 parts of Oxalis Sorrel were decocted with 12 times the amount of water for 3 times, each time for 1.5 hours, the filtrates were combined, and the filtrates were concentrated under reduced pressure to a crude drug content of 1 g / mL.

[0050] Example 3: Preparation of Oxalis Sorrel Water Extract

[0051] 100 parts of Oxalis Sorrel were added with 10 times the amount of water and boiled for 2 times, each time for 1 hour, the filtrates were combined and concentrated under reduced pressure to a crude drug content of 0.5 g / mL.

[0052] Example 4: Preparation of Oxalis Sorrel Water Extract

[0053] 100 parts of Oxalis Sorrel were added with 10 times the amount of water and boiled for 2 times, each time for 1 hour, the filtrates were combined and concentrated under reduced pressure to a crude drug content of 0.2 g / mL.

[0054] Comparative Example 1: Preparation of Sophora flavescens aqueous extract

[0055] 100 parts of Sophora flavescens were decocted with 10 times the amount of water for 2 times, each time for 1 hour, the filtrates were combined and concentrated under reduced pressure to a crude drug content of 1 g / mL.

[0056] Comparative Example 2: Preparation of Phellodendron amurense aqueous extract

[0057] 100 parts of Phellodendron chinense were decocted with 10 times the amount of water for 2 times, each time for 1 hour, the filtrates were combined, and the crude drug content was concentrated under reduced pressure to 1 g / mL.

[0058] Comparative Example 3: Preparation of Honeysuckle Water Extract

[0059] Add 100 parts of honeysuckle to 10 times the amount of water and boil for 2 times, each time for 1 hour, combine the filtrate, and concentrate under reduced pressure to a crude drug content of 1 g / mL.

[0060] Comparative Example 4: Preparation of Radix Isatidis Water Extract

[0061] 100 parts of Radix Isatidis were decocted with 10 times the amount of water for 2 times, each time for 1 hour, the filtrates were combined, and the crude drug content was concentrated under reduced pressure to 1 g / mL.

[0062] In the above preparation examples, the "times" refers to the multiple of mass, as described above; for example, 1 kg of medicinal material plus 10 kg of water is called 10 times the amount of water. The "raw drug content" refers to the mass of the raw medicinal material contained in a unit volume of concentrated solution, as described above; for example, a raw drug content of 1 g / ml means: the raw drug content of 1000 ml of concentrated solution obtained by extracting 1000 g of medicinal material and concentrating it to 1000 ml.

[0063] 2. Anti-inflammatory effect experiment

[0064] 1. Experimental Materials

[0065] 1.1 Animals

[0066] Kunming mice, 4-5 weeks old, 20±2g, both male and female, were purchased from Beijing Weitonglihua Co., Ltd. and raised in a normal environment with free access to food and water. The experiment was conducted after 1 week of adaptive feeding.

[0067] 1.2 Medicines

[0068] Oxalis sorrel extract, prepared as in Example 1, crude drug content 1 g / mL;

[0069] Sophora flavescens extract, prepared in Comparative Example 1, with a crude drug content of 1 g / mL;

[0070] Phellodendron chinense extract, prepared in Comparative Example 2, crude drug content 1 g / mL;

[0071] Honeysuckle extract, prepared in Comparative Example 3, crude drug content 1 g / mL;

[0072] Radix Isatidis extract, prepared in Comparative Example 4, crude drug content 1 g / mL;

[0073] Aspirin effervescent tablets, purchased from AstraZeneca Pharmaceuticals Co., Ltd., specification: 0.5 g / tablet;

[0074] Xylene, a common commercial reagent.

[0075] 1.3 Instruments

[0076] BT224S electronic analytical balance.

[0077] 2. Anti-inflammatory effect experiment

[0078] 2.1 Experimental methods

[0079] 70 male Kunming mice of similar weight were selected. The groups and dosing conditions are shown in Table 1 below. Each group had 10 mice. The drugs were administered for 3 consecutive days. One hour after the last drug administration, 20 μL of xylene was applied to the front and back sides of the right ears of the animals. The left ears were not treated in any way to make inflammation model mice (see "Experimental Animals and Experimental Animal Models" edited by Du Lijun et al., 2012, pages 325-326). After 20 minutes, the animals in each group were killed by dislocating the cervical vertebrae, and the ears were carefully cut off along the auricle. Round ear pieces were punched at the same position with a 6mm diameter puncher, and weighed on an analytical balance. The swelling degree was calculated by subtracting the weight of the left ear from the weight of the right ear of each mouse. The swelling inhibition rate was calculated by the following formula as an indicator of the degree of inflammation.

[0080] Swelling inhibition rate = (swelling amount of model control group - swelling amount of experimental group) / swelling amount of model control group × 100%.

[0081] Table 1. Experimental groups

[0082]

[0083] 2.2 Data Analysis

[0084] PASW Statistics 18.0 software was used to perform statistical analysis on the experimental data. P < 0.05 indicated a significant difference, and P < 0.01 indicated an extremely significant difference.

[0085] 2.3 Experimental Results

[0086] The results of the anti-inflammatory effect assay are shown in Table 2 below.

[0087] Table 2. Effects of each group of samples on xylene-induced ear swelling in mice

[0088]

[0089] Note: Compared with the model control group, "*" indicates P < 0.05

[0090] As can be seen from Table 2, compared with the model control group, Example 1, Comparative Example 1, and Comparative Example 3 had a significant inhibitory effect on the ear swelling of mice induced by xylene, and the difference was significant (P<0.05). This result shows that Example 1 (Oxalis Sorrel water extract), Comparative Example 1 (Sophora flavescens water extract), and Comparative Example 3 (Lonicera japonica water extract) have a significant anti-inflammatory effect.

[0091] 3. The preventive and therapeutic effects on duck infectious serositis

[0092] 1. Experimental Materials

[0093] 1.1 Experimental animals and strains

[0094] Experimental animals: One-day-old ducklings (unimmunized) were purchased from Baohui Poultry Hatchery in Jizhou District, Tianjin, and raised to 2 weeks of age for the experiment; the experimental ducks were raised in a standard duck house with free access to food and water, and were fed antibiotic-free complete feed throughout the experiment.

[0095] Experimental strain: Riemerella anatipestifer, from the Virus Strain Center of the Shengtai Institute. This strain is a common strain that is available to the public, for example, it can be isolated from diseased ducks.

[0096] 1.2 Experimental drugs

[0097] The aqueous extracts of the traditional Chinese medicines prepared in Examples 1-4 and Comparative Examples 1-4.

[0098] 1.3 Experimental methods and grouping

[0099] 1.3.1 Preparation and control standards of Riemerella anatipestifer liquid for preparing duck infectious serositis animal model

[0100] Sterilized tryptic soy agar (TSA) and tryptic soy broth (TSB) were prepared, and 10% calf serum was added to serve as culture media for Riemerella anatipestifer.

[0101] Take the freeze-dried Riemerella anatipestifer basic seed, streak inoculate TSA plates, culture at 37°C for 16 to 24 hours under 5 to 10% CO2 conditions, pick several typical colonies, inoculate them into 100 to 200 ml TSB medium, culture at 37°C for 12 to 24 hours to harvest the bacterial solution; divide the bacterial solution into high-pressure sterilized 10 ml vials, 5 to 7 ml for each 10 ml vial.

[0102] Live bacteria count: The live bacteria content in the bacterial solution should be no less than 8×10 6 CFU / 0.2ml.

[0103] Storage and usage period: Store below -70℃, the usage period shall not exceed 7 days.

[0104] 1.3.2 Preparation of duck infectious serositis animal model

[0105] During bacterial challenge, 0.2 mL of the Riemerella anatipestifer solution prepared in Section 1.3.1 above was injected into each duckling to prepare a duck infectious serositis model duck; specifically, subcutaneous injection was used in the neck. One person fixed the duckling, and another person drew the cultured bacterial solution in advance, pinched the skin of the duckling's neck, and pierced and injected 0.2 ml of the bacterial solution into the triangle area formed by the neck and the skin. After the injection, the duckling was gently placed in the original cage, and the drug was administered by gavage every day. The experimental results of each group were recorded.

[0106] 1.3.3 Efficacy experiments

[0107] Except for the model control group and the blank control group, which were administrated with the same amount of water, the remaining groups were all administrated 2 days before modeling, and the administration method was oral administration to test the corresponding drugs in each administrated group; the model group was administrated with drinking water. As mentioned above, on the day of bacterial challenge, each group was subcutaneously injected with bacterial solution in the neck to establish the model. Each administrated group continued to be administrated for 6 days, and the mortality, clinical symptoms, mental state, feces color, and food and water intake of each group were continuously observed during the experiment. On the 7th day, the remaining ducks in each group were dissected, and the pericardium and periliver of the ducks in each group were observed and compared (the dead ducks during the experiment were counted according to the pericardium and periliver). Each group contained two parallel groups, each with 13 ducks, that is, each group contained a total of 26 ducks.

[0108] The experimental groups are shown in Table 3 below.

[0109] Table 3. Experimental groups

[0110]

[0111]

[0112] 1.3.4 Observation indicators

[0113] (1) Clinical symptoms

[0114] Sick ducks will have varying degrees of yellow-white or light green watery diarrhea, depression, serous or sticky secretions from the eyes and nose, "eye circles", decreased appetite, head retracted and wings drooping, fluffy feathers, weak legs and difficulty walking. As the disease worsens, some will show clinical symptoms such as head and neck tilted back, opisthotonos, convulsions, and feather contamination around the anus.

[0115] During the experiment, the mental state, behavioral activities, feeding and drinking water, feces of each group of ducks and the number of duck deaths in each group were observed and recorded.

[0116] (2) Infection and disease

[0117] The healthy control group was lively, with normal behavior and appetite. In contrast, the ducklings inoculated with bacteria showed obvious clinical symptoms such as depression, squatting in groups, and not wanting to eat.

[0118] (3) Infection mortality rate

[0119] Determination of death from Riemerella anatipestifer infection:

[0120] First, determine whether the death was caused by infection with Riemerella anatipestifer based on the pathological changes of each dead duck. If it cannot be determined based on the pathological changes, the strain is isolated for determination.

[0121] Specifically, during the experiment, ducks died suddenly after being inoculated with Riemerella anatipestifer or died after showing obvious clinical symptoms of Riemerella anatipestifer. Autopsy showed that most of them had visceral organ lesions caused by Escherichia coli disease. For those without typical clinical symptoms or pathological changes, strains were further isolated from the liver, heart blood or air sacs for confirmation. If the same Riemerella anatipestifer as the inoculated bacteria could be isolated, it was determined to be an infection and death.

[0122] The infection fatality rate is calculated as follows:

[0123] Infection mortality rate (%) = number of deaths in the group (birds) / number of experimental ducks in the group (birds) × 100%.

[0124] (4) Pericardial and hepatic rate

[0125] Autopsy of the diseased ducks revealed a thin layer of cellulose covering on the surface of the liver, and the liver was enlarged and brittle. Pericardial effusion contained cellulose exudates, and a large amount of cellulose villi were attached to the outer membrane of the heart with a long course of disease. The spleen was enlarged and mottled, and the meninges were congested and edematous. Checking the pathological conditions of the autopsied ducks, there was fibrinous pericarditis around the heart, some with cheesy exudates, the liver capsule was white and turbid, with cellulose attachments, and sometimes white necrotic spots were seen. If there was a phenomenon of capsule cellulose attachments in any part of the heart or liver, it was considered pericardial perihepatic, and dead ducks were also counted as pericardial perihepatic.

[0126] The calculation formula of pericardium and periliver rate is as follows:

[0127] Pericardial and hepatic pericardial rate = number of ducks with pericardial and hepatic pericardial ...

[0128] 1.3.5 Experimental results

[0129] (1) Clinical symptoms

[0130] After infection with Riemerella anatipestifer, the feed intake dropped sharply. The sick ducks would develop varying degrees of light green or grayish white watery diarrhea, depression, serous or sticky secretions from the eyes and nose, large eye circles, decreased appetite, head retracted and drooping wings, fluffy feathers, weak legs and difficulty walking. Some ducklings even had their head and neck tilted back, opisthotonos, and convulsions. Except for the blank group, ducklings died in all groups.

[0131] (2) Pathological changes

[0132] Figure 1 Figures A and B in the figure show the autopsy results of the surviving ducks in the blank control group and the model control group, respectively. Figure 1 It can be seen that compared with the blank control group, the ducklings in the model control group had increased pericardial fluid after inoculation with Riemerella anatipestifer, and the epicardial surface was covered with fibrinous exudate; in addition, in those with a longer course of disease, the pericardium and epicardium were adhered, the exudate on the surface of the liver was uniform and thin, and the liver was pale yellow or grayish white. The results fully demonstrated that the animal model of duck infectious serositis was successfully established.

[0133] (3) Infection mortality and pericardial and hepatic pericardial rates

[0134] The number of deaths of experimental ducks in each group during the experiment is shown in Table 4 below.

[0135] The infection mortality rate and pericardial and periliver infection rate of each group of experimental ducks are shown in Table 5. The data of each group were statistically analyzed using the data analysis method described in Section 2.2 of "II. Anti-inflammatory Effect Experiment" above, and the significance of the differences between the groups is marked in Table 5.

[0136] Table 4. Number of deaths of experimental ducks in each group during the experiment (pieces)

[0137]

[0138] Table 5. Mortality and pericardial and hepatic pericardial mortality of each group of experimental ducks (%)

[0139]

[0140] Note: Different letters indicate significant differences between the two groups.

[0141] It can be seen from Tables 4 and 5 that, compared with the model control group, the infection mortality rate and pericardial infection rate of the Oxalis water extract treatment group of Examples 1-4 were significantly reduced, while there was no significant difference in the other Chinese medicine water extract treatment groups of Comparative Examples 1-4; this shows that the Oxalis water extract can significantly reduce the mortality rate and pericardial infection rate caused by Riemerella anatipestifer infection, thereby having a significant therapeutic effect on duck infectious serositis caused by Riemerella anatipestifer.

[0142] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of Oxalis oxalis or its extract in the preparation of a medicament for preventing and / or treating poultry infectious serositis.

2. Use of Oxalis oxyphylla or its extract in the preparation of a medicament for preventing and / or treating inflammatory diseases in poultry.

3. The use according to claim 1, characterized in that The poultry infectious serositis is selected from duck infectious serositis, goose infectious serositis and chicken infectious serositis.

4. The use according to claim 1, characterized in that The poultry infectious serositis is duck infectious serositis.

5. The use according to claim 4, characterized in that The duck infectious serositis is caused by Riemerella anatipestifer.

6. The use according to any one of claims 1 to 5, characterized in that: The Oxalis extract is a water extract of Oxalis.

7. The use according to claim 6, characterized in that The aqueous extract of Oxalis oxyphylla is prepared by the following method: S1: decoct Oxalis with water to extract, and filter the extract; S2: The above decoction and filtration procedures are repeated several times; S3: The multiple filtrates obtained in step S2 are combined and concentrated to obtain.

8. The use according to claim 7, characterized in that In step S1, 10-15 times the amount of water is used to decoct and extract the Oxalis powder; And / or, in step S1, each decoction time is 1-2 hours; and / or, in step S2, the decoction and filtration procedures are repeated 2-3 times; And / or, in step S3, the concentration is reduced pressure concentration, preferably concentrated to a crude drug content of 0.3 to 2 g / mL, preferably 0.5 to 1 g / mL.

9. The use according to any one of claims 1 to 8, characterized in that The medicine is a medicine with the Oxalis or its extract as the only active ingredient, or a medicine composition with it as one of the active ingredients.

10. The use according to any one of claims 1 to 9, characterized in that: The drug is administered orally; Preferably, the oral administration includes mixing with feed, administering with drinking water or directly administering orally; Preferably, the drug is prepared in the form of an oral preparation; further preferably, the oral preparation is selected from oral solutions, suspensions, tablets, and capsules.

Citation Information

Patent Citations

  • Traditional Chinese medicine capable of preventing and treating infectious serositis of ducks and preparation method of traditional Chinese medicine

    CN107715005A

  • Application of traditional Chinese medicine composition to preparation of medicines for treating infectious serositis of ducks

    CN109700869A